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Does anticoagulation 
prevent thrombosis 
for persons with fractures 
distal to the hip?
■ Evidence-Based Answer 
Low-molecular-weight heparin (LMWH) prophy-
laxis significantly reduces the total incidence of
deep venous thrombosis (DVT) for patients with
lower-limb fractures managed with surgical fixa-
tion and cast immobilization (strength of recom-
mendation [SOR]: A, based on multiple random-
ized controlled studies [RCTs]). Evidence is insuf-
ficient to show whether LMWH specifically
reduces the risk of clinically significant DVTs, and
recommendations on its use are conflicting (SOR:
C, based on expert opinion). Evidence is insuffi-
cient to recommend for or against warfarin pro-
phylaxis for DVT in fractures distal to the hip
(SOR: C, based on expert opinion). 
■ Evidence Summary
Thrombotic complications are common in lower-
limb fractures. In 1968, a prospective observation-
al study evaluated the natural history of DVT and
pulmonary embolism (PE) in tibial fractures treat-
ed with open reduction and internal fixation with
early mobilization. Seventy-six consecutive
patients with 79 tibial fractures were evaluated
with venograms, most within 1 month of injury.
The overall incidence of thrombosis was 45%.
Half were minor, involving 1 to 3 of the paired
deep venous trunks of the lower leg without clini-
cal signs of embolism. Twelve patients (16%) had
extensive thrombosis, involving 4 to 6 of the deep
venous trunks. Three of these had nonfatal PE
diagnosed clinically, and 1 had a fatal PE con-
firmed at autopsy. The mean age of those with
extensive thrombosis or PE was 54 years, and
these events were uncommon below age 25 years.1
Incidence of DVT and PE was also evaluated
in a cohort of 102 unselected patients who under-
went operative fixation for lower-limb fractures,
excluding patella, ankle, and foot fractures. All
underwent venography approximately 9 days
after fixation and were followed clinically for 6
weeks. The overall incidence of DVT was 28%
(40% with femoral shaft, 43% with tibial plateau,
22% with tibial shaft, and 12% with tibial pla-
fond [distal articular tibia]). Four developed clini-
cal evidence of PE during hospitalization but only
1 had objective confirmation. None of the patients
showed clinical evidence of PE as outpatients.2
LMWH prophylaxis significantly reduced
thrombosis in patients with lower-limb fractures
in 3 out of 4 RCTs. The first RCT evaluated 253
patients with lower-limb fractures immobilized 
in plaster casts after surgical fixation. Half 
the patients received subcutaneous LMWH
(nadroparin [Fraxiparin], a European LMWH
similar to enoxaparin), and half received no
thrombosis prophylaxis. Based on compression
ultrasound at the time of cast removal (17 days
postinjury, on average), the overall DVT incidence
was 11%. Six patients (5%) receiving LMWH
had DVTs vs 21 (17%) in the control group (num-
ber needed to treat [NNT]=8 to prevent 1 DVT
detectible by compression ultrasound). Two thirds
of patients with DVT were asymptomatic. One
third had clinical signs of DVT, including 1 patient
diagnosed with PE on clinical grounds. There was
no difference in bleeding complications between
the treatment groups.3
A second RCT evaluated LMWH (Mono-
Embolex, a European LMWH) prophylaxis in 328
outpatients with lower limb injuries, which includ-
ed fractures, severe contusions, and ligamentous
injuries. All were treated nonsurgically with cast
immobilization (mean=18.8 days, range=2–72
days) and 176 patients used daily LMWH injec-
tions. All underwent Doppler evaluation for leg
thromboses after cast removal, and positive results
were confirmed with venograms. Overall, there
were no DVTs among the LMWH prophylaxis
group and 7 DVTs (4.3%) in the group without
LMWH prophylaxis (P<.006). Among those with
fractures, the untreated DVT rate was 5.9% (vs
0% with LMWH prophylaxis). Those over age 40
who did not use LMWH had a DVT rate of
11.4% (vs 1.7% in younger patients). Without
LMWH prophylaxis, casting for more than 10
days approximately doubled the risk of DVT com-
pared with less than 10 days (6.1% vs 3.1%). This
study did not report on the anatomic location of
DVTs or if they were clinically evident.4
The third RCT evaluated reviparin (another
European LMWH) vs placebo in 440 outpatients
with lower limb injuries, of whom 293 had frac-
tures. About half had surgical management and all
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were treated with a plaster cast or brace for an
average of 44 days. Most were ambulatory with
crutches. All underwent venography within a week
of cast removal. The DVT rate for fracture patients
using reviparin was 10.4%, vs 18.2% among those
without LMWH prophylaxis (absolute risk reduc-
tion=7.8%; NNT=12.8). Three fourths of the
DVTs were in distal veins, and 21% of the DVTs
in the LMWH patients occurred in deep veins
compared with 34% in patients without. Two pul-
monary emboli occurred, both in patients without
LMWH prophylaxis.5
The final RCT evaluated tinzaparin (yet
another European LMWH) in 300 adult outpa-
tients immobilized in plaster for at least 3 weeks.
Most patients (205 out of 300) underwent venog-
raphy, and the overall DVT rate was 10% (tinza-
parin) vs 17% (controls). Among the 150 fracture
patients who underwent venography, the DVT
rate was 11% (tinzaparin) vs 13% (controls). This
difference was not significant, probably due to
insufficient numbers. None of the DVTs was clin-
ically detectable.6
In hip fracture and hip arthroplasty, warfarin
and LMWH are both effective in preventing
thrombosis. No studies have specifically evaluated
warfarin prophylaxis in lower extremity fractures
or compared it with LMWH.
■ Recommendations from Others
The American College of Chest Physicians (ACCP)
says that LMWH prophylaxis reduces the risk of
asymptomatic DVTs and is standard of care in
Europe. The ACCP does not recommend throm-
boprophylaxis for isolated lower extremity 
fractures in the US because of cost and insufficient
evidence of clinically important reduction in
venous thromboembolism (VTE). However, ACCP
lists unspecified “lower extremity or pelvic 
fracture” as a risk factor for VTE, and does recom-
mend that trauma patients with at least 1 risk 
factor for VTE receive thromboprophylaxis. They
make no recommendation about the use of 
warfarin.7
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■ Clinical Commentary
Although LMWH costs more than daily
warfarin, it has fewer complications
LMWH has largely replaced warfarin for DVT
prevention in lower extremity fractures in our
clinic. Subsequently, screening for warfarin’s
drug-drug interactions and measuring the
PT/INR levels to adjust patient doses are no
longer needed. LMHW provides effective DVT
prevention without laboratory monitoring. Even
though LMWH costs significantly more than
daily warfarin, the complications associated
with warfarin use, or no prophylaxis therapy 
at all, could be substantially greater. We do not
typically use prophylactic anticoagulation on
ankle fractures, but we do routinely put high-
risk patients with tibia, fibula, and femur frac-
tures on aspirin and LMWH. In our experience,
we have not had a patient develop a DVT while
on LMWH prophylaxis.
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